10:20 , Jun 13, 2019 |  BC Extra  |  Tools & Techniques

GSK teams up with Doudna, Weissman labs to create CRISPR genomics center

GlaxoSmithKline’s latest move to reinvigorate R&D is a collaboration with two of the biggest names in CRISPR research to develop new gene editing technologies and use them to identify drug targets. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)...
03:07 , Jun 7, 2019 |  BC Innovations  |  Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
22:33 , May 2, 2019 |  BC Innovations  |  Product Development

Evelo breaks from the microbiome pack with non-colonizing bugs

While most companies developing bugs as drugs want their microbes to flourish in hosts, Evelo is designing microbial candidates that exert therapeutic effects without colonizing, replicating or metabolizing -- acting more like biologics than live...
22:46 , Apr 16, 2019 |  BC Extra  |  Preclinical News

Mounting a mitochondrial attack to starve the inflammasome

While companies are directly inhibiting NLRP3 to treat a swath of inflammatory diseases, at least one academic group is shutting down the protein’s upstream mitochondrial triggers. The approach, from University of California San Diego researchers,...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
01:34 , Mar 23, 2019 |  BioCentury  |  Tools & Techniques

A frequentist and a Bayesian walk into a trial

In the stand-off between Bayesians and frequentists, the latter own the show for pivotal trials. But with non-profits leading the drive, Bayesians are poised to enter late-stage development via platform trials in cancer. The next...
22:14 , Mar 1, 2019 |  BioCentury  |  Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
20:08 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Seventure leads Axial's $25M series B

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...
13:00 , Feb 27, 2019 |  BC Extra  |  Financial News

Seventure leads Axial's $25M series B

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs. Existing investors Longwood Fund, Domain Associates and Heritage Medical...
19:35 , Feb 13, 2019 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Osteoarthritis Patient sample and mouse studies suggest inhibiting the CH25H-RORA axis could help treat osteoarthritis. In patients, mRNA and protein levels of CH25H and RORA, two factors on the cholesterol metabolism pathway in chondrocytes,...